Latest News
Latest Financial Results
Q2 2026
Quarter Ended Jun 30, 2026
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2025
Report Links
Email Alerts
Sign up today and receive company updates straight to your inbox.
Company Overview
BullFrog AI harnesses artificial intelligence and machine learning to advance pharmaceutical R&D and drug target discovery, providing AI-accelerated outputs that are optimized and human-validated.
BullFrog AI operates through three complementary capabilities, deployable independently or as a combined platform: bfPREP™ for biology-aware data harmonization, bfLEAP® for causal AI analytics and patient subgroup discovery, and bfARENAS™ for structured, auditable decision support. The common thread across all three: every output is traceable, every analytical decision is logged, and every recommendation is designed to be reviewed and validated by the scientific team before it drives a decision.
Our mission is to improve lives by identifying critical connections between therapies and highly responsive patients – in less time, with less cost, and more precision.
IR Contacts
Headquarters
BullFrog AI Holdings, Inc.
325 Ellington Blvd.
#317
Gaithersburg, MD 20878
T: 240-658-6710
info@bullfrogai.com
Investor Relations
Core IR
Rory Rumore
Senior Vice President, Investor Relations
377 Oak St
Garden City, NY 11530
USA
M: 1 (212) 655-0924
ir@bullfrogai.com
https://coreir.com
Transfer Agent
VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436
F: 646-536-3179
0-K@vstocktransfer.com